LV
Lundbeckfonden Ventures
Venture CapitalActiveLundbeckfonden Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by Lundbeck Foundation
53
Investments
5
Exits
$1.5B
AUM
9.4%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Lundbeckfonden Ventures.
Investment Thesis & Strategy
Lundbeckfonden Ventures invests in various stages of biotech companies, leveraging its evergreen structure to support long-term growth and innovation in the life sciences sector.
Investment Activity
Deals per year over the last 12 years
1
20111
20120
20131
20142
20150
20160
20172
20180
20190
20204
20211
2022Portfolio Companies
Selected investments from their portfolio of 53 companies
H
Hoba Therapeutics
Biotech · Series A, 2022
A
Adcendo
Biotech · Series A, 2021
S
Synklino
Biotech · Seed, 2021
N
NMD Pharma
Biotech · Series B, 2021
H
Hemab
Biotech · Series A, 2021
I
InProTher
Biotech · Series A, 2018
E
Evaxion Biotech
Biotech · Series A, 2018
C
Contera Pharma
Biotech · Series A, 2015
N
Nykode Therapeutics
Biotech · Growth, 2015
A
Avillion
Biotech · Growth, 2014
O
Orphazyme
Biotech · Series B, 2012
G
Galecto
Biotech · Series A, 2011
Notable Exits
CompanyTypeYearValue / Acquirer
Contera PharmaAcquisition2023—
GalectoIPO2021—
SanionaIPO2015—
AvillionAcquisition2014—
Zealand PharmaIPO2010—
Frequently Asked Questions
Lundbeckfonden Ventures focuses on Series A, Series B, Series C+ stage investments.